Lupin partners with Takeda to commercialise Vonoprazan
The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths - 10 mg and 20 mg
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vonoprazan
Alkem signs non-exclusive patent license agreement with Takeda to commercialise Vonoprazan in India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault’ (Vonoprazan) in…
Vonoprazan is a novel gastrointestinal drug and is a next generation treatment for gastro duodenal ulcer and GERD
Mankind Pharma signs non-exclusive patent license agreement with Takeda to commercialise Vonoprazan…
The agreement allows Mankind Pharma to launch the novel drug for treating GERD under its trademark
Cipla signs agreement with Takeda to commercialise Vonoprazan
This deal is meant to commercialise the drug in India under Cipla’s own trademark brands
Sun Pharma signs non-exclusive patent licensing agreement with Takeda for introducing Novel…
The new partnership aims to address widespread gastroesophageal reflux disease in India
Torrent pharma enters into non – exclusive patent licensing agreement with Takeda Pharma
The company aims to commercialise its gastrointestinal drug in India Torrent Pharmaceuticals recently announced that it has…